期刊
DIABETES OBESITY & METABOLISM
卷 19, 期 12, 页码 1655-1668出版社
WILEY
DOI: 10.1111/dom.13009
关键词
insulin therapy; insulin-associated weight gain; type 2 diabetes; obesity; weight loss interventions; predictors; mechanisms
资金
- Biomedical Research Program at Weill Cornell Medicine in Qatar - Qatar Foundation
- Qatar National Research Fund [NPRP 8-912-3-192]
- National Institute for Health Research [NF-SI-0513-10029] Funding Source: researchfish
Insulin therapy (IT) is initiated for patients with type 2 diabetes mellitus when glycaemic targets are not met with diet and other hypoglycaemic agents. The initiation of IT improves glycaemic control and reduces the risk of microvascular complications. There is, however, an associated weight gain following IT, which may adversely affect diabetic and cardiovascular morbidity and mortality. A 3 to 9 kg insulin-associated weight gain (IAWG) is reported to occur in the first year of initiating IT, predominantly caused by adipose tissue. The potential causes for this weight gain include an increase in energy intake linked to a fear of hypoglycaemia, a reduction in glycosuria, catch-up weight, and central effects on weight and appetite regulation. Patients with type 2 diabetes who are receiving IT often have multiple co-morbidities, including obesity, that are exacerbated by weight gain, making the management of their diabetes and obesity challenging. There are several treatment strategies for patients with type 2 diabetes, who require IT, that attenuate weight gain, help improve glycaemic control, and help promote body weight homeostasis. This review addresses the effects of insulin initiation and intensification on IAWG, and explores its potential underlying mechanisms, the predictors for this weight gain, and the available treatment options for managing and limiting weight gain.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据